Pembrolizumab 투여로 Pseudoprogression 이후 완전 관해에 도달한 호지킨 림프종 1예Complete Remission after Pseudoprogression in Refractory Classical Hodgkin Lymphoma Treated with Pembrolizumab
- Other Titles
- Complete Remission after Pseudoprogression in Refractory Classical Hodgkin Lymphoma Treated with Pembrolizumab
- Authors
- 홍주현[홍주현]; 배주환[배주환]; 이상글[이상글]; 임민기[임민기]; 고영혜[고영혜]; 김석진[김석진]; 김원석[김원석]
- Issue Date
- 2017
- Publisher
- 대한내과학회
- Keywords
- Hodgkin disease; Pembrolizumab; 호지킨림프종; 펨브롤리주맙
- Citation
- 대한내과학회지, v.92, no.4, pp.415 - 418
- Indexed
- KCI
- Journal Title
- 대한내과학회지
- Volume
- 92
- Number
- 4
- Start Page
- 415
- End Page
- 418
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/32507
- DOI
- 10.3904/kjm.2017.92.4.415
- ISSN
- 1738-9364
- Abstract
- Classical Hodgkin lymphoma (cHL) is a highly curable disease, but the prognosis for relapsed/refractory cHL is grave.
Pembrolizumab has recently shown impressive effects in patients with relapsed/refractory cHL in a phase Ib study (KEYNOTE-013). This report presents a case of a 17-year-old male with refractory cHL who received multiple chemotherapy regimens and radiotherapies, including brentuximab vedotin. Following both the second and fourth cycles of intravenous pembrolizumab 100 mg (2 mg/kg), positron emission tomography/computed tomography (PET/CT) scan showed progression.
However, because performance status and fever improved, treatment was continued, and complete remission was confirmed by PET/CT after eight cycles of pembrolizumab. This case suggests that clinicians need to be aware of the potential for pseudoprogression in patients treated with pembrolizumab.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/32507)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.